IDiyas

For the Inventor, By the Inventor

Schlieren, Switzerland

Molecular Partners Ag


USPTO Granted Patents = 22



Trademarks = 2

Forward Citations = 92

Loading Chart...
Loading Chart...

44 inventors (with patents filed for the assignee):

goldMedal Hans Kaspar Binz (14 out of 17 patents)

silverMedal Patrik Forrer (9 out of 15 patents)

bronzeMedal Michael Tobias Stumpp (7 out of 15 patents)

4.  Douglas Phillips (6 out of 6 patents)

5.  Frieder W Merz (6 out of 6 patents)

6.  Ignacio Dolado (5 out of 5 patents)

7.  Ivo Sonderegger (5 out of 5 patents)

8.  Daniel Steiner (5 out of 7 patents)

9.  Maya Gulotti-Georgieva (5 out of 5 patents)

10.  Talitha Bakker (4 out of 4 patents)

11.  Marcel Walser (4 out of 5 patents)

12.  Victor Levitsky (4 out of 4 patents)

13.  Johan Abram Saliba (3 out of 3 patents)

14.  Johannes Schilling (3 out of 3 patents)

15.  Heike Maria Strobel (2 out of 2 patents)


22 patents:

1. 12441772 - Designed ankyrin repeat domain with improved stability (2025-10-14),
2. 12435445 - Designed ankyrin repeat domains with altered surface residues (2025-10-07),
3. 12331090 - Multispecific proteins (2025-06-17),
4. 11834504 - DARPin based multi-specific t-cell engagers (2023-12-05),
5. 11578427 - Designed ankyrin repeat domains with altered surface residues (2023-02-14),
6. 11466062 - Ankyrin repeat binding proteins and their uses (2022-10-11),
7. 11453708 - Designed ankyrin repeat proteins binding to hepatocyte growth factor (2022-09-27),
8. 11332501 - Recombinant binding proteins and their use (2022-05-17),
9. 10717772 - Recombinant binding proteins targeting HER2 and serum albumin, and their uses (2020-07-21),
10. 10646542 - Modified binding proteins inhibiting the VEGF-A receptor interaction (2020-05-12),
11. 10370414 - Binding proteins comprising at least two repeat domains against HER2 (2019-08-06),
12. 10322190 - Capping modules for designed ankyrin repeat proteins (2019-06-18),
13. 10155791 - Recombinant binding proteins and their use (2018-12-18),
14. 9849158 - Modified binding proteins inhibiting the VEGF-A receptor interaction (2017-12-26),
15. 9775912 - Designed repeat proteins binding to serum albumin (2017-10-03),
Molecular Partners AG is a Swiss clinical-stage biopharmaceutical company specializing in the development of DARPin® therapeutics. DARPin® molecules, the company's proprietary technology, are highly specific and versatile antibody-derived in drug designs. Molecular Partners AG is focused on developing innovative therapies for serious diseases, including oncology, ophthalmology, and immunology.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

22 Patents

#4 in Schlieren

#547 in Switzerland

#27,863 in the World

...
Schlieren, Switzerland

Molecular Partners Ag

Forward Citations = 92

44 inventors:

goldMedal Hans Kaspar Binz (14 out of 17 patents)

silverMedal Patrik Forrer (9 out of 15 patents)

bronzeMedal Michael Tobias Stumpp (7 out of 15 patents)

4.  Douglas Phillips (6 out of 6 patents)

5.  Frieder W Merz (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com
Loading…